← Back to Search

Unknown

Kinezodianone R hydrochloride for Ocular Hypertension

Phase 1 & 2

Waitlist Available

Research Sponsored by Laboratoires Thea

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Both eyes diagnosed with open-angle glaucoma or ocular hypertension

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 22 days

Awards & highlights

Study Summary

This trial is testing the safety of a new drug, T4090.

Who is the study for?

This trial is for individuals with open-angle glaucoma or ocular hypertension in both eyes who have signed an informed consent. It's not suitable for those allergic to the trial medication, pregnant or breastfeeding women, or anyone with recent eye trauma or significant inflammation.Check my eligibility

What is being tested?

The study is testing T4090 eye drops containing Kinezodianone R hydrochloride against a placebo to assess their safety in treating patients with ocular hypertension or glaucoma.See study design

What are the potential side effects?

While specific side effects are not listed, they may include typical reactions related to eye drop use such as discomfort, redness, itching, swelling, and possible allergic responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

Both of my eyes have been diagnosed with glaucoma or high eye pressure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 22 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 22 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 22 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Ocular and systemic adverse events

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: T4090Experimental Treatment1 Intervention

Group II: PlaceboPlacebo Group1 Intervention

named "Vehicle" in the study protocol.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Laboratoires TheaLead Sponsor

54 Previous Clinical Trials

6,450 Total Patients Enrolled

6 Trials studying Ocular Hypertension

2,372 Patients Enrolled for Ocular Hypertension

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total patient pool for this clinical trial?

"Yes, that is accurate. The clinicaltrials.gov website currently has information indicating that this study is looking for participants. This trial was originally posted on July 5th, 2020 and updated on July 18th, 2020. They are hoping to have 120 people join from 1 location."

Answered by AI

Are people with the specific disease required for this research study currently being recruited?

"That is correct. The information available on clinicaltrials.gov shows that this study is currently looking for participants. This trial was originally posted on 7/5/2022 and was updated most recently on 7/18/2022. So far, 1 site has been identified as a possible location for the trial, but the researchers are hoping to find 120 people in total to participate."

Answered by AI